Prospective Multicenter Registry Study of Multiple System Atrophy in China

Sponsor
Peking University First Hospital
Study ID
NCT07644013
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
40 Years - 75 Years
Healthy Volunteers
Accepted

Study Details

Multiple system atrophy is a rare, rapidly progressive neurodegenerative disease characterized by variable combinations of parkinsonism, cerebellar ataxia, and autonomic dysfunction. Existing natural history studies from North America, Europe, and Japan suggest that clinical phenotypes and disease progression may differ across populations. However, comprehensive multicenter prospective data from Chinese patients with multiple system atrophy remain limited. This prospective multicenter registry study aims to describe the clinical characteristics, longitudinal progression, and outcomes of Chinese patients with multiple system atrophy, to identify factors associated with disease progression and prognosis, and to establish a longitudinal cohort for future biomarker validation and clinical trial design.

Key Dates

First listed
Jun 12, 2026
Start date
Jun 1, 2025
Status verified
May 2026
Primary completion
Dec 31, 2029
Completion
Jun 30, 2030

Study Design

Enrollment
214 participants (estimated)

Arms

  • Arm: MSA
  • Arm: PD
  • Arm: HC
    Healthy control / Control without neurodegenerative diseases

Primary Outcome Measure

Change in disease severity [ Time Frame: Baseline to up to 36 months after enrollment. ]

Central Contacts

Find similar trials

Nationwide
Parkinson's disease trialsNeurology trialsBrain disorders trials

Related Studies